Anti-insulin-like growth factor strategies in breast cancer
The insulin-like growth factors (IGF-I and -II) are potent mitogens and survival factors for both normal and malignant breast cells. These effects are mediated primarily through the IGF-I receptor (IGF-IR), which is significantly overexpressed and highly activated in breast tumors. The IGF-binding p...
Gespeichert in:
| Veröffentlicht in: | Seminars in oncology 2004-02, Vol.31 (1 Suppl 3), p.54-63 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 63 |
|---|---|
| container_issue | 1 Suppl 3 |
| container_start_page | 54 |
| container_title | Seminars in oncology |
| container_volume | 31 |
| creator | Jerome, Lori Shiry, Laura Leyland-Jones, Brian |
| description | The insulin-like growth factors (IGF-I and -II) are potent mitogens and survival factors for both normal and malignant breast cells. These effects are mediated primarily through the IGF-I receptor (IGF-IR), which is significantly overexpressed and highly activated in breast tumors. The IGF-binding proteins are competitive inhibitors of IGF/IGF-IR interaction, limiting cellular proliferation and survival. Higher serum IGF-I levels or an increased ratio of IGF-I to IGF binding protein-3 is associated with an increased risk of developing breast cancer. Hence, interest in the IGF system as a potential target for the development of novel antineoplastic therapies has ensued. Several strategies to interrupt IGF-IR signaling are currently being evaluated for the treatment of breast cancer, including suppression of IGF production, reduction of functional IGF-IR levels, neutralization of IGF action, and inhibition of IGF-IR activation. |
| doi_str_mv | 10.1053/j.seminoncol.2004.01.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71789065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093775404000259</els_id><sourcerecordid>71789065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-4318f931dc5e8600cfb6d22501a122cde8c8b99286889e44d0925791a19bf6443</originalsourceid><addsrcrecordid>eNqFkc1OwzAQhC0EoqXwCignxCVh7dixLU6l4k-qxAXOVuJsikuaFNsF8fakaiVu9LSH_WZGmiEkoZBREPnNMgu4cl3f2b7NGADPgGYA8oiMqchZqiSoYzIG0HkqpeAjchbCEoBRydgpGVEBggmej8nttIsudV3YtK5LW_eBycL33_E9aUobe5-E6MuIC4chcV1SeSxDTGzZWfTn5KQp24AX-zshbw_3r7OndP7y-DybzlPLcx5TnlPV6JzWVqAqAGxTFTVjAmhJGbM1KqsqrZkqlNLIeQ2aCamHr66agvN8Qq52vmvff24wRLNywWLblh32m2AklUpDIQbw-l-QKikULwb4oCeVRaGBbsPVDrS-D8FjY9berUr_YyiY7Rhmaf7GMNsxDFAzjDFIL_cZm2qF9Z9w3_4A3O0AHNr7cuhNsA6Hamvn0UZT9-5wyi8fqp56</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17669014</pqid></control><display><type>article</type><title>Anti-insulin-like growth factor strategies in breast cancer</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Jerome, Lori ; Shiry, Laura ; Leyland-Jones, Brian</creator><creatorcontrib>Jerome, Lori ; Shiry, Laura ; Leyland-Jones, Brian</creatorcontrib><description>The insulin-like growth factors (IGF-I and -II) are potent mitogens and survival factors for both normal and malignant breast cells. These effects are mediated primarily through the IGF-I receptor (IGF-IR), which is significantly overexpressed and highly activated in breast tumors. The IGF-binding proteins are competitive inhibitors of IGF/IGF-IR interaction, limiting cellular proliferation and survival. Higher serum IGF-I levels or an increased ratio of IGF-I to IGF binding protein-3 is associated with an increased risk of developing breast cancer. Hence, interest in the IGF system as a potential target for the development of novel antineoplastic therapies has ensued. Several strategies to interrupt IGF-IR signaling are currently being evaluated for the treatment of breast cancer, including suppression of IGF production, reduction of functional IGF-IR levels, neutralization of IGF action, and inhibition of IGF-IR activation.</description><identifier>ISSN: 0093-7754</identifier><identifier>EISSN: 1532-8708</identifier><identifier>DOI: 10.1053/j.seminoncol.2004.01.007</identifier><identifier>PMID: 15052543</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Humans ; Receptors, Somatomedin - antagonists & inhibitors ; Receptors, Somatomedin - metabolism ; Signal Transduction - drug effects</subject><ispartof>Seminars in oncology, 2004-02, Vol.31 (1 Suppl 3), p.54-63</ispartof><rights>2004 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-4318f931dc5e8600cfb6d22501a122cde8c8b99286889e44d0925791a19bf6443</citedby><cites>FETCH-LOGICAL-c434t-4318f931dc5e8600cfb6d22501a122cde8c8b99286889e44d0925791a19bf6443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.seminoncol.2004.01.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15052543$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jerome, Lori</creatorcontrib><creatorcontrib>Shiry, Laura</creatorcontrib><creatorcontrib>Leyland-Jones, Brian</creatorcontrib><title>Anti-insulin-like growth factor strategies in breast cancer</title><title>Seminars in oncology</title><addtitle>Semin Oncol</addtitle><description>The insulin-like growth factors (IGF-I and -II) are potent mitogens and survival factors for both normal and malignant breast cells. These effects are mediated primarily through the IGF-I receptor (IGF-IR), which is significantly overexpressed and highly activated in breast tumors. The IGF-binding proteins are competitive inhibitors of IGF/IGF-IR interaction, limiting cellular proliferation and survival. Higher serum IGF-I levels or an increased ratio of IGF-I to IGF binding protein-3 is associated with an increased risk of developing breast cancer. Hence, interest in the IGF system as a potential target for the development of novel antineoplastic therapies has ensued. Several strategies to interrupt IGF-IR signaling are currently being evaluated for the treatment of breast cancer, including suppression of IGF production, reduction of functional IGF-IR levels, neutralization of IGF action, and inhibition of IGF-IR activation.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Humans</subject><subject>Receptors, Somatomedin - antagonists & inhibitors</subject><subject>Receptors, Somatomedin - metabolism</subject><subject>Signal Transduction - drug effects</subject><issn>0093-7754</issn><issn>1532-8708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1OwzAQhC0EoqXwCignxCVh7dixLU6l4k-qxAXOVuJsikuaFNsF8fakaiVu9LSH_WZGmiEkoZBREPnNMgu4cl3f2b7NGADPgGYA8oiMqchZqiSoYzIG0HkqpeAjchbCEoBRydgpGVEBggmej8nttIsudV3YtK5LW_eBycL33_E9aUobe5-E6MuIC4chcV1SeSxDTGzZWfTn5KQp24AX-zshbw_3r7OndP7y-DybzlPLcx5TnlPV6JzWVqAqAGxTFTVjAmhJGbM1KqsqrZkqlNLIeQ2aCamHr66agvN8Qq52vmvff24wRLNywWLblh32m2AklUpDIQbw-l-QKikULwb4oCeVRaGBbsPVDrS-D8FjY9berUr_YyiY7Rhmaf7GMNsxDFAzjDFIL_cZm2qF9Z9w3_4A3O0AHNr7cuhNsA6Hamvn0UZT9-5wyi8fqp56</recordid><startdate>20040201</startdate><enddate>20040201</enddate><creator>Jerome, Lori</creator><creator>Shiry, Laura</creator><creator>Leyland-Jones, Brian</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040201</creationdate><title>Anti-insulin-like growth factor strategies in breast cancer</title><author>Jerome, Lori ; Shiry, Laura ; Leyland-Jones, Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-4318f931dc5e8600cfb6d22501a122cde8c8b99286889e44d0925791a19bf6443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Humans</topic><topic>Receptors, Somatomedin - antagonists & inhibitors</topic><topic>Receptors, Somatomedin - metabolism</topic><topic>Signal Transduction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jerome, Lori</creatorcontrib><creatorcontrib>Shiry, Laura</creatorcontrib><creatorcontrib>Leyland-Jones, Brian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jerome, Lori</au><au>Shiry, Laura</au><au>Leyland-Jones, Brian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-insulin-like growth factor strategies in breast cancer</atitle><jtitle>Seminars in oncology</jtitle><addtitle>Semin Oncol</addtitle><date>2004-02-01</date><risdate>2004</risdate><volume>31</volume><issue>1 Suppl 3</issue><spage>54</spage><epage>63</epage><pages>54-63</pages><issn>0093-7754</issn><eissn>1532-8708</eissn><abstract>The insulin-like growth factors (IGF-I and -II) are potent mitogens and survival factors for both normal and malignant breast cells. These effects are mediated primarily through the IGF-I receptor (IGF-IR), which is significantly overexpressed and highly activated in breast tumors. The IGF-binding proteins are competitive inhibitors of IGF/IGF-IR interaction, limiting cellular proliferation and survival. Higher serum IGF-I levels or an increased ratio of IGF-I to IGF binding protein-3 is associated with an increased risk of developing breast cancer. Hence, interest in the IGF system as a potential target for the development of novel antineoplastic therapies has ensued. Several strategies to interrupt IGF-IR signaling are currently being evaluated for the treatment of breast cancer, including suppression of IGF production, reduction of functional IGF-IR levels, neutralization of IGF action, and inhibition of IGF-IR activation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15052543</pmid><doi>10.1053/j.seminoncol.2004.01.007</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0093-7754 |
| ispartof | Seminars in oncology, 2004-02, Vol.31 (1 Suppl 3), p.54-63 |
| issn | 0093-7754 1532-8708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71789065 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Antineoplastic Agents - pharmacology Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Humans Receptors, Somatomedin - antagonists & inhibitors Receptors, Somatomedin - metabolism Signal Transduction - drug effects |
| title | Anti-insulin-like growth factor strategies in breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T20%3A42%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-insulin-like%20growth%20factor%20strategies%20in%20breast%20cancer&rft.jtitle=Seminars%20in%20oncology&rft.au=Jerome,%20Lori&rft.date=2004-02-01&rft.volume=31&rft.issue=1%20Suppl%203&rft.spage=54&rft.epage=63&rft.pages=54-63&rft.issn=0093-7754&rft.eissn=1532-8708&rft_id=info:doi/10.1053/j.seminoncol.2004.01.007&rft_dat=%3Cproquest_cross%3E71789065%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17669014&rft_id=info:pmid/15052543&rft_els_id=S0093775404000259&rfr_iscdi=true |